AU2017319306B2 - Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof - Google Patents

Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof Download PDF

Info

Publication number
AU2017319306B2
AU2017319306B2 AU2017319306A AU2017319306A AU2017319306B2 AU 2017319306 B2 AU2017319306 B2 AU 2017319306B2 AU 2017319306 A AU2017319306 A AU 2017319306A AU 2017319306 A AU2017319306 A AU 2017319306A AU 2017319306 B2 AU2017319306 B2 AU 2017319306B2
Authority
AU
Australia
Prior art keywords
week
cell
val
leu
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017319306A
Other languages
English (en)
Other versions
AU2017319306A1 (en
Inventor
Gary Abrams
Tushar Ganjawala
Qi Lu
Zhuo-Hua Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2017319306A1 publication Critical patent/AU2017319306A1/en
Application granted granted Critical
Publication of AU2017319306B2 publication Critical patent/AU2017319306B2/en
Priority to AU2022201291A priority Critical patent/AU2022201291B2/en
Priority to AU2024200016A priority patent/AU2024200016B9/en
Priority to AU2025248765A priority patent/AU2025248765A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017319306A 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof Active AU2017319306B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2022201291A AU2022201291B2 (en) 2016-08-29 2022-02-25 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2024200016A AU2024200016B9 (en) 2016-08-29 2024-01-02 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2025248765A AU2025248765A1 (en) 2016-08-29 2025-10-13 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380871P 2016-08-29 2016-08-29
US62/380,871 2016-08-29
PCT/US2017/049158 WO2018044912A1 (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201291A Division AU2022201291B2 (en) 2016-08-29 2022-02-25 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017319306A1 AU2017319306A1 (en) 2019-04-11
AU2017319306B2 true AU2017319306B2 (en) 2021-12-02

Family

ID=59859616

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017319306A Active AU2017319306B2 (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2022201291A Active AU2022201291B2 (en) 2016-08-29 2022-02-25 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2024200016A Active AU2024200016B9 (en) 2016-08-29 2024-01-02 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2025248765A Pending AU2025248765A1 (en) 2016-08-29 2025-10-13 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2022201291A Active AU2022201291B2 (en) 2016-08-29 2022-02-25 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2024200016A Active AU2024200016B9 (en) 2016-08-29 2024-01-02 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2025248765A Pending AU2025248765A1 (en) 2016-08-29 2025-10-13 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Country Status (15)

Country Link
US (3) US11041004B2 (https=)
EP (1) EP3504227A1 (https=)
JP (1) JP7116884B2 (https=)
KR (3) KR102609571B1 (https=)
CN (2) CN110023327B (https=)
AU (4) AU2017319306B2 (https=)
BR (1) BR112019003950A2 (https=)
CA (1) CA3034887A1 (https=)
IL (2) IL265010B2 (https=)
MX (1) MX2019002321A (https=)
MY (1) MY197491A (https=)
NZ (1) NZ751983A (https=)
RU (1) RU2019109021A (https=)
SG (2) SG10202102061SA (https=)
WO (1) WO2018044912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN113173984B (zh) 2021-04-12 2022-08-30 中眸医疗科技(武汉)有限公司 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用
MX2024007770A (es) * 2021-12-20 2024-07-01 Genans Biotechnology Co Ltd Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5).
EP4665750A1 (en) 2023-02-17 2025-12-24 Ray Therapeutics, Inc. Gene therapy compositions and methods for treating diseases of the retina
WO2025137649A1 (en) * 2023-12-22 2025-06-26 Wayne State University Method of enhancing viral mediated gene delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150223679A1 (en) * 2014-02-07 2015-08-13 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
KR100922422B1 (ko) 2006-06-27 2009-10-16 가부시키가이샤 어드밴테스트 반도체 시험 장치 및 반도체 메모리의 시험 방법
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
KR101945962B1 (ko) 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2013071231A1 (en) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsins for optical control of cells
CA2866405A1 (en) * 2012-03-05 2013-09-12 Wayne State University Identification of channelopsin-2 (chop2) mutations and methods of use
EP2968476B1 (en) * 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
EP4678754A3 (en) 2014-03-11 2026-04-08 Wayne State University A modified mglur6 promoter and methods of use
WO2015161308A1 (en) 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
WO2016179038A1 (en) 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
LT3436051T (lt) 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
WO2017210664A1 (en) 2016-06-03 2017-12-07 Massachusetts Institute Of Technology Somatic opsins for single cell resolution optogenetics
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150223679A1 (en) * 2014-02-07 2015-08-13 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof

Also Published As

Publication number Publication date
IL265010B1 (en) 2024-02-01
SG11201901697QA (en) 2019-03-28
JP7116884B2 (ja) 2022-08-12
US11041004B2 (en) 2021-06-22
RU2019109021A (ru) 2020-09-29
WO2018044912A1 (en) 2018-03-08
KR102609571B9 (ko) 2025-11-20
IL310142A (en) 2024-03-01
EP3504227A1 (en) 2019-07-03
JP2019528781A (ja) 2019-10-17
AU2024200016B2 (en) 2025-07-17
AU2024200016A1 (en) 2024-01-25
BR112019003950A2 (pt) 2019-06-25
CA3034887A1 (en) 2018-03-08
KR20250159068A (ko) 2025-11-07
US20250163111A1 (en) 2025-05-22
US12234267B2 (en) 2025-02-25
KR20230169427A (ko) 2023-12-15
NZ751983A (en) 2025-11-28
AU2022201291B2 (en) 2023-10-05
MY197491A (en) 2023-06-19
IL265010A (https=) 2019-04-30
AU2024200016B9 (en) 2025-08-07
KR20190075906A (ko) 2019-07-01
KR102609571B1 (ko) 2023-12-01
AU2022201291A1 (en) 2022-03-17
CN119979612A (zh) 2025-05-13
MX2019002321A (es) 2019-10-21
US20220089660A1 (en) 2022-03-24
SG10202102061SA (en) 2021-04-29
US20190241628A1 (en) 2019-08-08
RU2019109021A3 (https=) 2021-02-02
AU2025248765A1 (en) 2025-10-30
AU2017319306A1 (en) 2019-04-11
IL265010B2 (en) 2024-06-01
KR102877327B1 (ko) 2025-10-27
CN110023327B (zh) 2024-02-27
CN110023327A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
AU2022201291B2 (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
US8470790B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
EP2315833B1 (en) Vectors for delivery of light-sensitive proteins and methods of use
EP3117002B1 (en) A modified mglur6 promoter and methods of use
US20220088222A1 (en) Compositions and methods for the treatment of degenerative ocular diseases
EP4536694A1 (en) Melanopsin variants for vision restoration
BR122024010814A2 (pt) Vetor de expressão de vírus adeno-associado (aav) ou de vírus adenoassociado recombinante (raav), composição farmacêutica, usos dos mesmos, e método para alterar a condutividade de uma membrana
WO2023285987A1 (en) Retgc gene therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAMES OF CO-INVENTORS GANJAWALA, TUSHAR; LU, QI AND ABRAMS, GARY

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAMES OF CO-INVENTORS GANJAWALA, TUSHAR; LU, QI AND ABRAMS, GARY